Associate Professor
Swansea University Medical School
Telephone: (01792) 295158
Email: JavaScript is required to view this email address.
Room: Academic Office - 428
Fourth Floor
Institute of Life Science 1
Singleton Campus

George is a steering member of the International Life Science Institute (ILSI) Health and Environmental Sciences Institute (HESI) Genetic Toxicology Technical Committee (GTTC) and co-chair of the quantitative and mode of action subgroups. The ILSI-HESI provides an international forum to advance the understanding of scientific issues related to human health, toxicology, risk assessment, and the environment.

George has been invited to give oral presentations and chair sessions at most of the major international Toxicology conferences in recent years. The IWGT was a particular highlight, and the resulting consensus statements have been published in a series of manuscripts that provide expert advice, these manuscripts have a history of influencing ICH, OECD and other regulatory policy revisions, and will thus be of international impact.

George has been lead academic on numerous international collaborations. These include US-FDA-NCTR, Health Canada, RIVM-Netherlands, AstraZeneca, Drugs for Neglected Disease Initiative (DNDi), Food Standards Agency, GlaxoSmithKline, Gentronix, Hoffman-La-Roche, Litron, and more. He also continues to co-lead the DNA damage group (in vitro Toxicology group) in the Institute of Life Science, as well as teaching on the Genetics Degree programme, and having a role as Director of Employability and Entrepreneurship for the Medical School.

George was awarded the prestigious UKEMS Young Scientist Award in 2012, in 2013 he became a Fellow of the Higher Education Academy, and in 2014 he became a British & European Registered Toxicologist and also won the very prestigious EEM(G)S Young Scientist Award.

In June 2017 George was voted in as President-Elect for the EEMGS society, and will become President in 2019. 

George has recently become a consultant, with clients including the pharmaceutical, food additive and chemical industries. A major aspect of many of these projects has been the derivation of point of departure metrics for use in human health risk assessments. Please contact him for further information on his services, which he runs through Swansea Innovations

Areas of Expertise

  • Genetic Toxicology
  • Mutation Testing
  • DNA Repair
  • Risk Assessment
  • Point of Departure
  • Dose Response Modelling


  1. & A novel, integrated in vitro carcinogenicity test to identify genotoxic and non-genotoxic carcinogens using human lymphoblastoid cells. Archives of Toxicology, 1-7.
  2. & Comparing BMD-derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay. Environmental and Molecular Mutagenesis
  3. & Empirical analysis of BMD metrics in genetic toxicology part I:in vitroanalyses to provide robust potency rankings and support MOA determinations. Mutagenesis 31(3), 255-263.
  4. & Empirical analysis of BMD metrics in genetic toxicology part II:in vivopotency comparisons to promote reductions in the use of experimental animals for genetic toxicity assessment. Mutagenesis 31(3), 265-275.
  5. & Genetic Toxicology at the Crossroads – From Qualitative Hazard Evaluation to Quantitative Risk Assessment. Mutagenesis 31
  6. & A comparison of the genotoxicity of benzo[a]pyrene in four cell lines with differing metabolic capacity. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 808, 8-19.
  7. & Genetic toxicology at the crossroads—from qualitative hazard evaluation to quantitative risk assessment. Mutagenesis 31(3), 233-237.
  8. & Measuring Reproducibility of Dose Response Data for the Pig-a Assay using Covariate Benchmark Dose Analysis. Mutation Research/Genetic Toxicology and Environmental Mutagenesis
  9. & Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations. Environmental and Molecular Mutagenesis
  10. & Development of an in vitro PIG-A gene mutation assay in human cells. Mutagenesis 32(2), 283-297.
  11. & Evaluation of the automated MicroFlow® and Metafer™ platforms for high-throughput micronucleus scoring and dose response analysis in human lymphoblastoid TK6 cells. Archives of Toxicology
  12. & Dose–response relationship of temozolomide, determined by the Pig-a, comet, and micronucleus assay. Archives of Toxicology
  13. & Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents. Mutation Research/Reviews in Mutation Research
  14. & Genotoxicity of flubendazole and its metabolitesin vitroand the impact of a new formulation onin vivoaneugenicity. Mutagenesis 31(3), 309-321.
  15. & The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency. Mutagenesis, gev069
  16. & Correlation of in vivo versus in vitro benchmark doses (BMDs) derived from micronucleus test data: A proof of concept study. Toxicological Sciences 148(2), 355-367.
  17. & MutAIT: an online genetic toxicology data portal and analysis tools. Mutagenesis, gev050
  18. & A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis. PLOS Neglected Tropical Diseases 9(9), e0003889
  19. & Theoretical considerations for thresholds in chemical carcinogenesis. Mutation Research/Reviews in Mutation Research 765, 56-67.
  20. & Estimating the carcinogenic potency of chemicals from thein vivomicronucleus test. Mutagenesis 31(3), 347-358.

See more...


  • PM-120 Genetic Analysis I

    This module will give assignments designed to develop skills in essay writing and oral presentations. It will also look at the principles and practice of internet searching for scientific sources.

  • PM-200 Genetic Analysis II

    This module will give assignments designed to build on essay writing and oral presentation skills introduced in level 1. It will also develop critical evaluation, analysis skills for the understanding of peer-reviewed research papers.

  • PM-226 Human and Medical Genetics

    The course is designed to introduce fundamental concepts in the study of human genetics with particular reference to the application of the principles to medicine. The course covers the role of genetics in human health and disease and methods for the detection of genetic variability in human populations.

  • PM-300 Medical Genetics

    The course is designed to provide an advanced study of the identification of human genes and the determination of the influence of human genes upon disease and health status. Gene identification provides targets for the development of new pharmaceuticals and the range of variation present in the population.

  • PM-304 Biomolecular Research Project


  • PM-316 Genetic Toxicology

    The module provides an advanced understanding of the effects of carcinogenic agents on human health, and develops skills in investigating and assessing DNA damage caused by genotoxic compounds to improve the prevention and treatment of cancer and human disease.

  • PM-E01 Placement Year

    On successful completion of the industrial placement year, the student should: have gained first-hand experience of working in a commercial scientific research and development team, appreciate the differences between an academic and industrial working environment.

  • PM-M16 Nano(geno)toxicology

    Nano(geno)toxicology is a new discipline that has recently evolved with the development of the nanotechnology industry. This subject encompasses general toxicology associated with nanomaterials and also specifically focuses on the sub-discipline of genotoxicology. This course will therefore focus on, (I) the parameters of engineered nanomaterials that govern their interaction and influence on biological systems; (II) techniques that are central elements in assessing the safety evaluation of nanomaterials; (III) portals of entry into the body, their potential fate and the mechanisms that underlie cellular damage by nanomaterials.

  • PM-M28 Nano(geno)toxicology

    PM-M28 is a Taught Masters level module that focusses upon the field of Nanoparticle (geno)toxicology. The module is worth 20 credits. It occurs in the second semester, and is administered through both lecture-based and practical components. Students are taught by a variety of lecturers from academia, industry and clinical medicine. Students are assessed via both coursework (two (2) pieces) and examination. Briefly, Nano(geno)toxicology is a new, multi-interdisciplinary discipline that has evolved concomitantly with the development of the nanotechnology industry. The syllabus of this taught module encompasses general toxicology associated with nanomaterials (hazard and exposure assessments), their genetic toxicology implications, their physical and material properties as well as their applied formulations and scenarios. The module further provides insight into all these areas from the view of not only academia, but also industry and clinical medicine.


  • Untitled (current)

    Student name:
    Other supervisor: Dr James Cronin
    Other supervisor: Dr George Johnson
  • Untitled (current)

    Student name:
    Other supervisor: Dr George Johnson
    Other supervisor: Dr Geertje Van Keulen
  • Untitled (current)

    Student name:
    Other supervisor: Dr James Cronin
    Other supervisor: Dr George Johnson
  • Multiplexed in vitro assay for genetic toxicology screening (current)

    Student name:
    Other supervisor: Prof Paul Rees
    Other supervisor: Dr James Cronin
    Other supervisor: Dr George Johnson

Administrative Responsibilities

  • Enterprise & Innovation Committee Member - College of Medicine

    2013 - Present

  • Director of Employability and Entrepreneurship - College of Medicine

    2012 - Present

  • Learning & Teaching Committee Member - College of Medicine

    2011 - Present

  • Genetics & Biochemistry Board of Studies Member - College of Medicine

    2007 - Present

  • Chair - Student Staff Consultative Committee - College of Medicine

    2011 - 2013

  • Member - Collaborative Provision Committee

    2014 - Present

  • Member - HEAR Steering Team

    2013 - Present

  • Member - Entrepreneurial Learning City Region Steering Group

    2014 - Present

  • Member - University - Committee for Research & Innovation Strategy

    2016 - Present

External Responsibilities

Research Groups

  • Genetic Toxicology Quantitative Research

    This Swansea based group links to international groups including the ILSI-HESI GTTC quantitative group and the IWGT 2013 quantitative group, both of which Dr George Johnson takes a leading role on, and both of which show global impact through their membership and publications. The aim of the GTQR group is to use Genetic Toxicology data in a more quantitative manner for human health risk assessment, and the work to date has initiated this paradigm shift, with the group now building on this success.

  • In Vitro Toxicology (DNA Damage) Research

    The in vitro Toxicology (DNA Damage) Research group is led by Professor Gareth Jenkins, Dr Shareen Doak and Dr George Johnson and aims to develop in vitro approaches to assess the hazards and risks posed to our genome from exposure to both natural and man-made agents.